Drugs & Therapy Perspectives

, Volume 21, Issue 5, pp 23–26 | Cite as

Pharmacists have many opportunities to aid in the management of acid-peptic disorders

Practical Issues and Updates

References

  1. 1.
    Weart CW, Leider H. Opportunities for pharmacists to aid in the management of acid-peptic disorders. Dis Manage Health Outcomes 2004; 12(4): 239–47CrossRefGoogle Scholar
  2. 2.
    Pinson JB, Weart CW. Acid-peptic products. In: Covington TR, Berardi RR, Young LL, et al., editors. Handbook of nonprescription drugs. Washington, DC: American Pharmaceutical Association, 2002: 193–224Google Scholar
  3. 3.
    ASHP Commission on Therapeutics. ASHP therapeutic position statement on the identification and treatment of Helicobacter-associated peptic ulcer disease in adults. Am J Health Syst Pharm 2001; 58(4): 331–7Google Scholar
  4. 4.
    Howden CW, Hunt RW. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998; 93: 2330–8PubMedCrossRefGoogle Scholar
  5. 5.
    Kahrilas PJ. Gastroesophageal reflux disease and its complications. In: Feldman M, Scharschmidt BF, Sleisenger MH, editors. Sleisenger & Fordtran’s gastrointestinal and liver disease. Philadelphia (PA): WB Saunders Company, 1998: 498–507Google Scholar
  6. 6.
    Soll AH, for the Practice Parameters Committee of the American College of Gastroenterology. Consensus statement: medical treatment of peptic ulcer disease: practice guidelines. JAMA 1996; 275: 622–9PubMedCrossRefGoogle Scholar
  7. 7.
    Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2037–46PubMedCrossRefGoogle Scholar
  8. 8.
    DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005 Jan; 100(1): 190–200PubMedCrossRefGoogle Scholar
  9. 9.
    Berardi RR. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Am J Manag Care 2000; 6(9 Suppl.): S491–505PubMedGoogle Scholar
  10. 10.
    Williams DB. Gastroesophageal reflux disease. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: a pathophysiologic approach. Stamford (CT): Appleton & Lange, 1999: 532–47Google Scholar
  11. 11.
    Kahrilas PJ. Gastroesophageal reflux disease and its complications. In: Feldman M, Scharschmidt BF, Sleisenger MH, editors. Sleisenger & Fordtran’s gastrointestinal and liver disease. Philadelphia (PA): WB Saunders Company, 1998: 498–507Google Scholar
  12. 12.
    Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 276: 983–8PubMedCrossRefGoogle Scholar
  13. 13.
    Berardi RR. Peptic ulcer disease. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: a pathophysiologic approach. Stamford (CT): Appleton & Lange, 1999: 548–70Google Scholar
  14. 14.
    Levin TR, Schmittdiel JA, Henning JM, et al. A cost analysis of a Helicobacter pylori eradication strategy in a large health maintenance organization. Am J Gastroenterol 1998; 93: 743–7PubMedCrossRefGoogle Scholar
  15. 15.
    Jones GT, Morreale AP. Cost-benefit computer modeling of Helicobacter pylori testing and treatment in patients on long-term H2-blocker prophylaxis. J Manag Care Pharm 2000; 6: 383–9Google Scholar

Copyright information

© Adis Data Information BV 2005

Personalised recommendations